A study to test how well different doses of BI 764532 are tolerated by people with a tumour in the brain that is positive for DLL3

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501766-22-01

Acronym

1438-0003

Enrollment

Registered

2024-04-16

Start date

2024-04-23

Completion date

Unknown

Last updated

2025-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma expressing DLL3

None listed

Sex/Gender

All

Age

18 Years to No maximum

Austria, Germany, Netherlands, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026